The study aims to enhance U.S. public health preparedness through the Walgreens community pharmacy network, improving access and diversity in clinical trials via a $25 million award.
Neutrogena, Walgreens and the Melanoma Research Foundation came together to provide information and resources, including free skin cancer screenings and education on effective products.
Shrank brings extensive healthcare experience, business leadership and clinical expertise to WBA board as the company undergoes a strategic turnaround.
WBA lowered its fiscal 2024 adjusted EPS guidance to $2.80 to $2.95 reflecting challenging pharmacy industry trends and a worse-than-expected U.S. consumer environment.